5-Amino-1MQ vs Epitalon.

5-Amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule, substrate-site inhibitor of the enzyme nicotinamide N-methyltransferase (NNMT). Despite being grouped with "peptides" in the research-chemical marketplace, it is not a peptide at all but a methylquinolinium heterocyclic salt that emerged from academic medicinal-chemistry work at the University of Texas aimed at producing membrane-permeable NNMT inhibitors. It is an investigational research compound, not an approved drug.

Epitalon (also spelled Epithalon or Epithalone; sequence Ala-Glu-Asp-Gly, abbreviated AEDG) is a synthetic tetrapeptide developed in the 1980s by the Russian gerontologist Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology. It was designed to reproduce the proposed active fragment of Epithalamin, a crude peptide extract of the bovine pineal gland, and is classified as a short "peptide bioregulator." It is not a small-molecule drug or a hormone; the corresponding AEDG sequence was reported to be detectable in physiological pineal tissue only in 2017.

NNMT is a cytosolic enzyme that transfers a methyl group from S-adenosylmethionine (SAM) to nicotinamide, generating 1-methylnicotinamide (1-MNA) and S-adenosylhomocysteine (SAH). Because nicotinamide is the precursor for NAD+ salvage, high NNMT activity in adipose tissue is thought to drain nicotinamide away from NAD+ synthesis and consume SAM. By occupying the nicotinamide substrate site, 5-Amino-1MQ lowers cellular 1-MNA and is proposed to spare nicotinamide for NAD+ regeneration and free up SAM-cycle methylation capacity. The downstream hypothesis (elevated NAD+ activating sirtuins/AMPK to favor energy expenditure over lipid storage) is mechanistically plausible but is largely inferred from cell and rodent work rather than directly demonstrated in humans.

The most cited proposed mechanism is activation of telomerase: in cultured human somatic cells, Epitalon has been reported to induce telomerase reverse transcriptase expression, lengthen telomeres, and extend the number of cell divisions past normal replicative (Hayflick) limits. A second proposed mechanism is epigenetic/gene-regulatory: AEDG is a short, cell-penetrating peptide that is hypothesized to bind directly to specific DNA promoter regions and modulate transcription, with reported effects on melatonin-synthesis enzymes (e.g., AANAT), interleukin-2, and neuronal differentiation genes. It has also been described as modulating pineal melatonin output and as having antioxidant effects in animal and Drosophila models. Importantly, after roughly 25 years of research the authoritative 2025 review concludes the true mechanism of action remains unclear, and some findings (e.g., on melatonin secretion) directly conflict between studies.

The core evidence is preclinical. Neelakantan et al. (Biochemical Pharmacology, 2018) reported that methylquinolinium NNMT inhibitors including 5-Amino-1MQ were membrane-permeable, relatively selective, lowered intracellular 1-MNA, and reduced lipogenesis in 3T3-L1 adipocytes; in diet-induced obese mice on a high-fat diet, systemic NNMT-inhibitor treatment significantly reduced body weight, white adipose mass, and adipocyte size and lowered plasma total cholesterol without changing food intake or producing observable adverse effects. Supporting context comes from Ehebauer et al. (Life Sciences, 2020) on glucose-dependent NNMT regulation in adipocytes, and Dimet-Wiley et al. (Scientific Reports, 2022) combining NNMT inhibition with calorie restriction in obese mice. There are no published human clinical trials, and no human pharmacokinetic or efficacy data for 5-Amino-1MQ have been reported. The human-vs-animal gap here is large and should not be glossed over.

Most evidence is preclinical (cell culture, Drosophila, mice, and rats), where Epitalon and Epithalamin have shown telomere lengthening and antioxidant effects; in some rodent lifespan experiments from Khavinson's group, they also reduced tumor incidence and extended mean lifespan. Human data are far thinner and come almost entirely from the same Russian research network. The most-cited human report (Khavinson & Morozov, Neuro Endocrinol Lett 2003, PMID 14523363) describes a 6–8 year follow-up of 266 elderly subjects in which Epithalamin (the pineal extract, not synthetic Epitalon) and thymalin were associated with reduced mortality versus controls; a related 15-year follow-up was published in 2011 (PMID 22451889). There are also small open-label reports in retinitis pigmentosa and a circadian/melatonin study. These studies are open-label, often unblinded, frequently use the crude extract rather than the synthetic tetrapeptide, and have not been independently replicated by Western randomized controlled trials. The human-vs-preclinical gap is large and unresolved.

Documented safety data are limited to short rodent studies, in which investigators reported no overt adverse effects at the doses tested; this is not a substitute for human safety characterization. There are no published human toxicology, drug-interaction, long-term, or reproductive-safety data. Theoretical concerns include the broad and context-dependent roles of NNMT and NAD+/SAM metabolism across tissues (liver, cancer, vasculature), the unknown consequences of chronically altering one-carbon/methylation flux, and the unverified purity and identity of material sold as a "research chemical." Because human safety is essentially uncharacterized, it should be regarded as an experimental compound of unknown human risk.

No rigorous, modern toxicology package exists for Epitalon. The 2025 International Journal of Molecular Sciences review explicitly states that data on this peptide's short- and long-term toxicity, genotoxicity, carcinogenic potential, and drug interactions are missing, and that these would be required before it could be approved as a pharmaceutical ingredient outside Russia. A specific theoretical concern is that a telomerase-activating compound could in principle promote survival or proliferation of abnormal cells, so its long-term oncologic safety in humans is genuinely unknown. Material sold for "research" use is unregulated, with no assurance of identity, purity, sterility, or endotoxin control. There are essentially no controlled human safety trials by Western standards.

5-Amino-1MQ is not approved by the FDA (or any major regulator) for any indication and is not a recognized dietary supplement; it is an investigational/research-use-only compound with no publicly documented IND or registered human clinical trials. It is not, as of this writing, a WADA-listed prohibited substance by name, though its NAD+/metabolic mechanism is the kind of area anti-doping bodies monitor.

Epitalon/Epithalamin reached clinical use only in Russia and has never been approved by the FDA or EMA; it is not an approved drug or dietary supplement in the United States and is sold there only as a research-use-only chemical. It is not a WADA-prohibited substance by name, though peptide-based agents can fall under broader anti-doping categories.